Zobrazeno 1 - 10
of 269
pro vyhledávání: ''
Publikováno v:
Breast Cancer Research and Treatment
Purpose Breast cancer survivors take vitamins and supplements to bolster their general health and to decrease the risk of cancer recurrence. Healthcare providers are frequently unaware of their patients non-prescription supplement use. The aim of thi
Publikováno v:
Breast Cancer Research and Treatment
PurposeMenopause is associated with an increased risk of estrogen receptor-positive (ER +) breast cancer. To characterize the metabolic shifts associated with reduced estrogen bioavailability on breast tissue, metabolomics was performed from ovary-in
Autor:
Robin Zon, Robert L Carolla, Robert B. Jenkins, Beiyun Chen, David W. Hillman, David B. Johnson, Edith A. Perez, Celyne Bueno, Alvaro Moreno-Aspitia, Alejandra T. Perez, Donald W. Northfelt, Roberto A. Leon-Ferre
Publikováno v:
Breast Cancer Res Treat
BACKGROUND: The addition of lapatinib (L) to trastuzumab (T) was previously found to be synergistic in preclinical models and in the neoadjuvant setting. Prior to the results of the ALTTO trial, this study assessed the safety and feasibility of addin
Autor:
Catarina Silva, Rosa Perestrelo, José S. Câmara, Marijana Petković, Ivo Sousa-Ferreira, Filipa Capelinha
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
One of the hallmarks of cancer cells is the demand of supply for the synthesis of new membranes involved in cell proliferation and lipids have an important role in cellular structure, signaling pathways and progression of cancer. In this sense, lipid
Publikováno v:
Breast Cancer Research and Treatment. 181:561-570
In this study we investigate the prediction and prognostic value of CXCL8–CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery. A total of 303 TNBC patients were
Publikováno v:
Translational Cancer Research
Breast Cancer Research and Treatment, 179(1), 131-138. Springer, Cham
Breast Cancer Research and Treatment, 179(1), 131-138. Springer, Cham
Purpose Breast cancer-related lymphedema (BCRL) is caused by an interruption of the lymphatic system after breast cancer treatment. Lymphaticovenous anastomosis (LVA), by which one or more patent lymphatic collecting vessels are connected to subcutan
Autor:
Lawrence H. Kushi, Andrew Rundle, Heather Greenlee, Zaixing Shi, Isaac J. Ergas, Jeanine M. Genkinger, Ying Kuen Cheung, Janise M. Roh, Marilyn L. Kwan
Publikováno v:
Breast Cancer Res Treat
PURPOSE: To identify distinct diet trajectories after breast cancer (BC) diagnosis, and to examine characteristics associated with diet trajectories. METHODS: We analyzed 2,865 Pathways Study participants who completed ≥2 food frequency questionnai
Autor:
Jongjin Kim, Sook Young Jeon, Jeong Hwan Park, Jiwoong Jung, Kyu Ri Hwang, Su jin Kim, Eun Youn Roh, Ki Tae Hwang, Jin Hyun Park, Byoung Hyuck Kim
Publikováno v:
Breast Cancer Research and Treatment. 179:139-151
To determine the long-term prognostic role of hormone receptor subtype in breast cancer using surveillance, epidemiology, and end results (SEER) database. Data of 810,587 female operable invasive breast cancer patients from SEER database with a mean
Autor:
Zhe Zhang, Aditya Bardia, Jennifer Y. Sheng, Anne Nguyen, Stacie Jeter, Daniel F. Hayes, Amanda L. Blackford, Raghunandan Venkat, Jon T. Giles, Vered Stearns, Gedge D. Rosson, Jill Hayden, Karineh Tarpinian, Anna Maria Storniolo, Norah Lynn Henry
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Aromatase inhibitors (AIs) are associated with musculoskeletal symptoms and risk of developing carpal tunnel syndrome (CTS), which can impair quality of life and prompt treatment discontinuation. The incidence of CTS and clinical utility of
Publikováno v:
Breast Cancer Research and Treatment. 175:525-530
Ado-trastuzumab emtansine (T-DM1/Kadcyla®;Genentech) is an antibody-drug conjugate used in the treatment of human epidermal growth factor receptor-2-positive metastasized breast cancer. Few studies report a spectrum of corneal changes in patients tr